HCA Healthcare 8-K, filed Jul 24, 2026

Summary

HCA Healthcare reported second-quarter 2026 results with revenues up 8.7% to $20.230 billion, net income up 2.8% to $1.699 billion and diluted earnings per share of $7.62, and its board declared a quarterly cash dividend of $0.78 per share payable September 30, 2026. The company said a payer mix shift from patients who lost health insurance exchange coverage cut income before income taxes by about $400 million in the quarter, partly offset by roughly $400 million of incremental net benefit from Medicaid supplemental payment programs, and it revised its full-year 2026 guidance ranges for revenue, net income, Adjusted EBITDA and EPS.

Key points

• Second-quarter 2026 revenues rose to $20.230 billion from $18.605 billion a year earlier; same facility admissions increased 2.5% and same facility equivalent admissions 2.7%.
• HCA revised its 2026 guidance to revenue of $77.000 to $79.500 billion, net income of $6.300 to $6.700 billion, Adjusted EBITDA of $15.400 to $16.100 billion and diluted EPS of $28.70 to $30.50.
• The company raised its estimated 2026 unfavorable impact from health insurance exchange payer mix to $1.000-$1.200 billion from $600-$900 million, and now expects a $300-$500 million net benefit from Medicaid supplemental payment programs.
• HCA recognized $1.372 billion of incremental revenue and $829 million of other operating expenses tied to Florida's directed payment program for October 1, 2024 through June 30, 2026, following CMS approval during the quarter.
• HCA repurchased 4.752 million shares for $2.064 billion in the quarter and had $7.210 billion remaining under its repurchase authorization as of June 30, 2026.

Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.